Home > Clinical Trials
Check All Search

Saved trials

ACTIVE_NOT_RECRUITING
NCT04784715
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
1,157 Enrollment(s)
283 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer; HER2-positive; Metastatic
RECRUITING
NCT04553770
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
88 Enrollment(s)
9 Study location(s)
INTERVENTIONAL (PHASE2)
Early-stage Breast Cancer


Hormone Receptor Positive Breast Carcinoma


Invasive Breast Cancer


Stage II Breast Cancer


Stage IIA Breast Cancer


Stage IIB Breast Cancer


Stage III Breast Cancer
RECRUITING
NCT05681702
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
90 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Artery Disease
NOT_YET_RECRUITING
NCT07198724
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
65 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer


HER2 Low Breast Carcinoma


HER2-negative Breast Cancer


Breast Cancer


Breast Cancer Female
RECRUITING
NCT07025148
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
40 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Arterial Disease (CAD)


Percutaneous Coronary Intervention (PCI)
WITHDRAWN
NCT04684212
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF
0 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (NA)
Atrial Fibrillation


Left Atrial Appendage Thrombosis


CVA
RECRUITING
NCT05950945
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
250 Enrollment(s)
84 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer
COMPLETED
NCT05103332
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
663 Enrollment(s)
110 Study location(s)
INTERVENTIONAL (PHASE2)
Hypertension